Topic

New Jersey

A collection of 536 issues

Denied for Darzalex/Darzalex Faspro by Cigna in New Jersey? Complete Appeal Guide (Templates & Timelines)

Answer Box: Your Path to Approval Cigna requires prior authorization for Darzalex/Darzalex Faspro in New Jersey, with appeals available through internal review (180 days) and New Jersey's IHCAP external review via Maximus Federal Services. Most denials stem from incomplete prior therapy documentation or non-formulary status. Start today:

Do You Qualify for Hemlibra Coverage by UnitedHealthcare in New Jersey? Complete Decision Tree & Appeals Guide

Answer Box: Your Path to Hemlibra Coverage UnitedHealthcare requires prior authorization for Hemlibra (emicizumab-kxwh) in New Jersey. You qualify if you have hemophilia A (with or without factor VIII inhibitors ≥5 Bethesda units) and need routine prophylaxis. No step therapy required. Submit via UnitedHealthcare Provider Portal with hemophilia A diagnosis,

How to Get Emflaza (deflazacort) Covered by Aetna (CVS Health) in New Jersey: Prior Authorization Guide and Appeals Process

Answer Box: Getting Emflaza (deflazacort) Covered by Aetna (CVS Health) in New Jersey Aetna requires prior authorization for Emflaza (deflazacort) with documented DMD diagnosis and failed trial of prednisone/prednisolone due to weight gain or behavioral issues. Submit genetic testing, prior steroid records, and medical necessity letter through CVS Caremark

How to Get Emgality (Galcanezumab) Covered by Cigna in New Jersey: Prior Authorization, Appeals, and Renewal Guide

Answer Box: Get Emgality Covered by Cigna in New Jersey Getting Emgality (galcanezumab-gnlm) covered by Cigna in New Jersey requires prior authorization with documented failure of 2+ standard migraine preventives and 4+ migraine days per month. Submit through your provider's Cigna portal with headache diary, prior therapy records,

Do You Qualify for Tysabri (Natalizumab) Coverage by Aetna (CVS Health) in New Jersey? Decision Tree & Next Steps

Answer Box: Your Fastest Path to Tysabri Coverage Likely eligible if: You have relapsing MS diagnosed by a neurologist, recent MRI showing disease activity, and documented inadequate response to other DMTs. Next steps: (1) Ensure TOUCH program enrollment, (2) gather JCV antibody test and baseline MRI, (3) submit Aetna'

How to Get Brensocatib (BRINSUPRI) Covered by Humana in New Jersey: Prior Authorization, Appeals, and Medical Necessity Requirements

Answer Box: Getting Brensocatib (BRINSUPRI) Covered by Humana in New Jersey Brensocatib (BRINSUPRI) requires prior authorization from Humana for non-cystic fibrosis bronchiectasis patients ≥12 years old. Submit PA via Humana provider portal with CT scan confirmation, pulmonologist consultation, and documentation of ≥2 exacerbations (adults) or ≥1 (pediatrics) in the past

How to Get Tepezza (teprotumumab) Covered by Aetna CVS Health in New Jersey: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Tepezza Approved by Aetna CVS Health in New Jersey Aetna CVS Health requires prior authorization for Tepezza (teprotumumab-trbw, J-code J3241) to treat moderate-to-severe thyroid eye disease in adults 18+. Coverage is limited to one lifetime course of 8 infusions over 24 weeks. First step: Have your ophthalmologist

How to Get Ferriprox (deferiprone) Covered by Blue Cross Blue Shield in New Jersey: PA Requirements, Appeals, and State Protections

Answer Box: Getting Ferriprox Covered by Blue Cross Blue Shield in New Jersey Ferriprox (deferiprone) requires prior authorization from Blue Cross Blue Shield plans in New Jersey. Under New Jersey's Ensuring Transparency in Prior Authorization Act, insurers must respond within 72 hours for non-urgent requests and 24 hours

If Zanzalintinib (XL092) Isn't Approved by UnitedHealthcare in New Jersey: Formulary Alternatives & Exception Paths

Answer Box: Getting Zanzalintinib (XL092) Coverage in New Jersey Zanzalintinib (XL092) is investigational and typically denied by UnitedHealthcare outside clinical trials. Your fastest path: (1) Check trial eligibility at ClinicalTrials.gov—patients with ≤2 prior TKIs may qualify; (2) If ineligible, request medical exception through OptumRx for compassionate use with

Getting Zanzalintinib (XL092) Covered by Humana in New Jersey: Clinical Trial Access and Compassionate Use Guide

Quick Answer: Your Path to Zanzalintinib Access in New Jersey Zanzalintinib (XL092) is investigational and not FDA-approved, so Humana won't cover the drug itself—but you have two main paths: clinical trials (free drug) or compassionate use (free drug, insurance covers monitoring). In New Jersey, if Humana denies